Sign up
ZVSA

ZyVersa Therapeutics Inc. (NASDAQ: ZVSA)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. The borrow fee is 9.26%. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

Momentum—

—

Trend—

—

Short interest—

—

ZVSA price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

ZVSA · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

—/100—

Latest available: Nov 13, 2026 · updates irregularly

Each axis is a 0 to 100 percentile rank among equities

Not scored: Equity peers

LiquidityNot scoredShortNot scoredSqueezeNot scoredTrendNot scoredMomentumNot scoredValuationNot scoredStabilityNot scored
What each one means
  • LiquidityNot scored

    Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.

  • ShortNot scored

    Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.

  • SqueezeNot scored

    Higher scores reflect a higher published Squeeze score within equity peers.

  • TrendNot scored

    Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.

  • MomentumNot scored

    Higher scores reflect stronger 63- and 126-session total returns within equity peers.

  • ValuationNot scored

    Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.

  • StabilityNot scored

    Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.

How the Q Score works →

Quantellect signals

— · Quantellect signals not available

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q1 2026−$0.40−$0.22—
Annual 2025—−$4.18—
Q3 2025—−$2.56—
Q2 2025—−$0.46—
Q1 2025—−$0.73—
Annual 2024—−$8.48—
Q3 2024−$1.60−$2.43—
Q2 2024−$3.75−$3.31—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All ZVSA news →

Company profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal

CEO
Mr. Stephen C. Glover
Headquarters
Weston, FL, United States
Employees
6
IPO date
Dec 12, 2022
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.